Longzheng Xia, Shiming Tan, Yujuan Zhou, Jingguan Lin, Heran Wang, L. Oyang, Yutong Tian, Lu Liu, Min Su, Hui Wang, D. Cao, Q. Liao
2018.4.11OncoTargets and Therapy
tlooto Summary
Current understanding of the NFκB-signaling pathway in cancer is updated and targeted therapies against effectors in oncogenic signaling have improved the outcomes of cancer patients.
Abstract
Cancer is a group of cells that malignantly grow and proliferate uncontrollably. At present, treatment modes for cancer mainly comprise surgery, chemotherapy, radiotherapy, molecularly targeted therapy, gene therapy, and immunotherapy. However, the curative effects of these treatments have been limited thus far by specific characteristics of tumors. Abnormal activation of signaling pathways is involved in tumor pathogenesis and plays critical roles in growth, progression, and relapse of cancers. Targeted therapies against effectors in oncogenic signaling have improved the outcomes of cancer patients. NFκB is an important signaling pathway involved in pathogenesis and treatment of cancers. Excessive activation of the NFκB-signaling pathway has been documented in various tumor tissues, and studies on this signaling pathway for targeted cancer therapy have become a hot topic. In this review, we update current understanding of the NFκB-signaling pathway in cancer.
Citation format
XIA, Longzheng, et al. Role of the nfκb-signaling pathway in cancer. OncoTargets and Therapy, 2018, 11: 2063–2073.